<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01500096</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00071671</org_study_id>
    <nct_id>NCT01500096</nct_id>
  </id_info>
  <brief_title>American Ginseng to Improve HIV-Associated Fatigue: A Randomized, Placebo-Controlled, Parallel Design, Multiple-Dose Clinical Trial</brief_title>
  <official_title>American Ginseng to Improve HIV-Associated Fatigue: A Randomized, Placebo-Controlled, Multiple-Dose Escalation Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether American ginseng is effective in the
      treatment of HIV-associated fatigue.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN Chronic fatigue is a major problem for HIV-infected patients and contributes to
      decreased quality of life and physical functioning, higher levels of psychological distress,
      and antiretroviral non-adherence. The etiology of fatigue in HIV-infected patients is
      unknown, but changes in systemic inflammation may play a contributing role. The mechanism of
      action of ginseng in the treatment of fatigue is also not clear, but in its role as a
      purported &quot;adaptogen,&quot; it may decrease fatigue by altering systemic inflammation. Ginseng is
      one of the most popular botanical products in the US and is marketed to improve fatigue and
      vitality. Our preliminary data suggested that American ginseng at 1000-2000 mg/day may
      decrease fatigue in cancer patients. HIV-infected patients frequently use ginseng, in part
      because they perceive these therapies to be safer than more conventional therapies.

      We hypothesized that a standardized American ginseng formulation will improved HIV-related
      fatigue. To test this hypothesis we propose a 6-week double-blind, placebo-controlled trial,
      parallel study of four weeks of treatment involving two doses of American ginseng or placebo
      (1000mg/day or 3000 mg/day) in 120 HIV-infected patients with clinically significant fatigue,
      as defined by their scores on the Fatigue Severity Scale. Patients will be treated with
      American ginseng or placebo every morning for a total of two doses of 1000 mg/day or 3000
      mg/day. A smaller cohort of 12 out of 120 subjects will be enrolled initially to monitor
      closely for confirmed virologic failure, If confirmed virologic failure is not observed,
      enrollment will continue to the proposed 120 subjects. Virologic failure is defined as two
      consecutive plasma viral loads &gt;200 cells according to the 2012 Department of Health Humans
      Services Guidelines for the use of antiretroviral agents in HIV-1 infected adults and
      adolescents

      The proposed doses of American ginseng are the same as those used in our previous trials.
      American ginseng 1000 mg/day showed efficacy in ameliorating fatigue in cancer patients. The
      highest dose of American ginseng (3000 mg/day) selected for this study was derived from our
      previous American ginseng trial.

      Change on scores of the Fatigue Severity Scale (FSS) between American ginseng and placebo
      groups at baseline, and treatment weeks 2, 4, and 6 (the last safety visit two weeks after
      completing the 4-week treatment period with American ginseng or placebo) will be calculated.
      The primary comparison of interest will involve the primary endpoint of the average change in
      the FSS scale score from baseline to the end of treatment. Other instruments to supplement
      the FSS and further assess fatigue will be a modified version of the Brief Fatigue Inventory
      (BFI), The Epworth Sleepiness Scale (ESS), the Patient Health Questionnaire (PHQ-9), Insomnia
      Severity Index (ISI), the Medical Outcomes Study HIV Health Survey (MOS-HIV), the Clinical
      Global Impressions (CGI) of Change Scale, and Patient-Reported Outcomes Measurement
      Information System (PROMIS) fatigue. To further elucidate the mechanism of HIV-related
      fatigue, we will evaluate the effects of American ginseng and placebo on markers of systemic
      inflammation such as IL-6 and soluble receptors of tumor necrosis factor (TNF) α 1 and 2
      (sTNFR1 and sTNFR2), at baseline and weeks 2, 4, and 6. cluster of differentiation 4 (CD4)
      cell counts, plasma HIV RNA levels, and adverse events (AEs) will also be assessed for safety
      purposes.

      DURATION:

      The total duration of this study is 6 weeks. Participants will receive American ginseng or
      placebo during the first 4 weeks of the study. On week 6 participants will complete their
      final post treatment safety study visit.

      POPULATION AND SAMPLE SIZE:

      120 HIV-infected subjects (40 in the American ginseng 1000 mg/day arm, 40 in the American
      ginseng 3000 mg/day arm, 20 in the placebo 1000 mg/day arm, and 20 in the placebo 3000 mg/day
      arm).

      REGIMEN:

      This is a randomized, placebo-controlled, longitudinal, parallel study with two doses of
      American ginseng. As shown in the study schematic figure, two doses of American ginseng or
      placebo (1000 or 3000 mg/day) will be given to 120 HIV-infected patients (40 in the American
      ginseng 1000 mg/day arm, 40 in the American ginseng 3000 mg/day arm, 20 in the placebo 1000
      mg/day arm, and 20 in the placebo 3000 mg/day arm) with clinically significant fatigue.
      Participants will receive American ginseng or placebo for a total of 4 weeks and will be
      followed for a total of 6 weeks (week 6 is the last safety visit 2 weeks after completing the
      4-week treatment period with American ginseng or placebo).

      American ginseng will be continued for Grades 1 and 2 toxicities at the discretion of the
      investigator. Treatment will be discontinued for subjects experiencing any grade ≥3 study
      drug toxicity. Evaluations for the early termination visit will be completed for these
      subjects. Participants who discontinue treatment secondary to toxicity will be followed until
      resolution, return to baseline values, or an adequate explanation can be given for their
      condition. Subjects requiring dose modifications/reductions/interruptions of American
      ginseng/placebo to manage toxicities will be followed off study drugs. The total number of
      patients accrued hence will be 120 patients (40 in the American ginseng 1000 mg/day arm, 40
      in the American ginseng 3000 mg/day arm, 20 in the placebo 1000 mg/day arm, and 20 in the
      placebo American ginseng 3000 mg/day arm).

      STUDY DURATION The total duration of this study is six weeks. Participants will receive
      American ginseng or placebo during the first 4 weeks of the study. On week 6 participants
      will complete their final post treatment safety study visit.

      STUDY AGENT/INTERVENTION DESCRIPTION Two doses of American ginseng or placebo (1000 mg/day or
      3000 mg/day) every morning by mouth for a 4-week period.

      PRIMARY AND SECONDARY OBJECTIVES The overall objective of this study is to determine the
      effect of American ginseng on fatigue in HIV-infected subjects. HIV-infected subjects with
      fatigue will be randomized to receive two doses (1000 mg/day or 3000 mg/day) of standardized
      American ginseng or placebo, and their levels of fatigue and quality of life will be
      assessed. We will also quantify proinflammatory cytokines in the placebo and American
      ginseng-treated groups to further elucidate the mechanism of HIV-related fatigue, and the
      effects of American ginseng on these markers.

      ENDPOINTS

      Primary Endpoint: Change in FSS total score from baseline to end of four weeks of treatment.

      Secondary Endpoints: Change from baseline and values observed at 2, 4, and 6 weeks
      post-baseline for the following measures: BFI-global assessment score ESS score PHQ-9 total
      score ISI score MOS-HIV scale total score, Gene Importance Calculator (GIC) score PROMIS
      fatigue scale score Serum cytokines (IL-6, sTNFR1, sTNFR2) CD4 cell counts, proportion with
      detectable plasma HIV RNA, AEs will be measured using the Division of AIDS Table for Grading
      the Severity of Adults Adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Fatigue Severity Score (FSS)</measure>
    <time_frame>From baseline to week 4 (28 days of study drugs)</time_frame>
    <description>Change in FSS score from baseline to Week 4. The change in fatigue as measured by the FSS (Week 4 minus Baseline) using the Wilcoxon test. The FSS is a scale score ranging from 1 to 63 with higher scores indicative of more fatigue. A negative number indicates a decline in the FSS scale. Participants with FSS data at both times points were assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Brief Fatigue Inventory</measure>
    <time_frame>Change in BFI scores from baseline to week 4 (28 days of study drugs)</time_frame>
    <description>Questionnaire: Change in the Brief Fatigue Inventory (BFI) from baseline to week 4. We compared BFI scores from baseline to week 4 in the ginseng 1000 and 3000 mg arms with the combined placebo arms. We used the BFI Question that assess &quot;Worst Fatigue&quot; score: 0 to 90 scale. Higher scores means more fatigue; negative values mean less fatigue.The BFI was used to supplement the data obtained from the FSS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Epworth Sleepiness Scale</measure>
    <time_frame>From baseline to week 4 (28 days of study drugs)</time_frame>
    <description>Questionnaire: Change in Epworth Sleepiness Scale (ESS) score from baseline to week 4. The ESS is scale ranges from 0 to 24; higher scores mean worse sleep disorder while a negative score indicates less sleep disorder. The ESS was used to supplement the data obtained from the FSS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Health Questionnaire 9</measure>
    <time_frame>From baseline to week 4 (28 days of study drugs)</time_frame>
    <description>Questionnaire: Change in Patient Health Questionnaire 9 (PHQ9) score from baseline to week 4. The scale for the PHQ9 score ranges from 0 to 27; higher scores mean worse depression; negative scores indicate less depression. We compared PHQ 9 scores from baseline to week 4 in the ginseng 1000 and 3000 mg arms with the combined placebo arms. The PHQ9 was used to supplement the data obtained from the FSS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insomnia Severity Index</measure>
    <time_frame>From baseline to week 4 (28 days of study drugs)</time_frame>
    <description>Questionnaire: Change in Insomnia Severity Index (ISI) score from baseline to week 4. The ISI scale ranges from 0 to 28; higher scores mean worse insomnia while negative scores indicate less insomnia. The ISI was used to supplement the data obtained from the FSS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Medical Outcomes Study HIV Health Survey</measure>
    <time_frame>From baseline to week 4 (28 days of study drugs)</time_frame>
    <description>Questionnaire: Change in Medical Outcomes Study (MOS) HIV Health Survey score from baseline to week 4. We evaluated the MOS Energy Fatigue scores; the MOS scale ranges from 0-100; higher scores mean more energy. The MOS was used to supplement the data obtained from the FSS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Clinical Global Impressions</measure>
    <time_frame>From baseline to week 4 (28 days of study drugs)</time_frame>
    <description>Questionnaire: Change in Clinical Global Impressions (CGI) scores from baseline to week 4. CGI is an instrument for making global assessments of worsening or improvement during interventional trials. The subject rates the change in the overall status since beginning the intervention (ranging from: very much improved, much improved, minimally improved, no change, and minimally worse). We assessed the number of participants who rated &quot;very much improved&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Markers</measure>
    <time_frame>From baseline to week 4 (28 days of study drugs)</time_frame>
    <description>Laboratory - Inflammatory Markers (IMs): Change in Interleukin (IL) -6 and soluble receptors of tumor necrosis factor (TNF) α 1 and 2 (sTNFR1 and sTNFR2) from baseline to week 4. Negative values indicate less change in inflammatory markers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4 Cell Count</measure>
    <time_frame>From baseline to week 5 (28 days of study drugs)</time_frame>
    <description>Laboratory: Change in absolute cluster of differentiation 4 (CD4) cell count from baseline to week 5. Negative values mean decline in CD4 cell count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma HIV RNA</measure>
    <time_frame>From baseline to week 4 (28 days of study drugs)</time_frame>
    <description>Laboratory: Change in plasma HIV RNA from baseline to week 4. A negative value means a drop in plasma HIV RNA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PROMIS Fatigue</measure>
    <time_frame>From baseline to week 4 (28 days of study drugs).</time_frame>
    <description>Questionnaire: Change in Patient-Reported Outcomes Measurement Information System (PROMIS) fatigue score from baseline to week 4. Change in PROMIS fatigue score from baseline to Week 4. The change in fatigue as measured by the PROMIS fatigue (Week 4 minus Baseline) using the Wilcoxon test. The PROMIS fatigue is a scale with normalized mean of 50 and standard deviation (SD) of 10. Higher mean values mean more fatigue and negative values indicate less fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events in the Ginseng and Placebo Arms</measure>
    <time_frame>From baseline to week 4 (28 days of study drugs)</time_frame>
    <description>Adverse events (AEs) were assessed from baseline to wk 4 using the NIH Division of AIDS (DAIDS) Grading Toxicity Table, a well known tool used by NIH networks for assessing the severity of AEs in participants enrolled in clinical trials. Reporting the number of participants in each arm who experienced adverse events.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>HIV/AIDS-associated Fatigue</condition>
  <arm_group>
    <arm_group_label>American ginseng 1000 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4-week of American ginseng 1000 mg/day every morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for American ginseng 1000 mg/day</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4-week of placebo for American ginseng 1000 mg/day every morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>American ginseng 3000 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4-week of American ginseng 3000 mg/day every morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for American ginseng 3000 mg/day</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4-week of placebo for American ginseng 3000 mg/day every morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>American ginseng</intervention_name>
    <description>American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
    <arm_group_label>American ginseng 1000 mg/day</arm_group_label>
    <arm_group_label>American ginseng 3000 mg/day</arm_group_label>
    <other_name>Panax quinquefolius</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo for American ginseng</intervention_name>
    <description>Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
    <arm_group_label>Placebo for American ginseng 1000 mg/day</arm_group_label>
    <arm_group_label>Placebo for American ginseng 3000 mg/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          1. HIV-infected men and women, ≥18 years of age

          2. HIV-1 infection documented by a rapid HIV test or any licensed ELISA test kit and
             confirmed by a repeat ELISA, Western blot at any time prior to study entry; or
             documentation of ongoing HIV/AIDS care, or treatment for AIDS, or previous positive
             HIV serology at any time prior to study entry

          3. On stable antiretroviral therapy for at least three months

          4. Undetectable plasma HIV RNA using conventional assays with lower limits of
             quantification (20-75 copies/ml) obtained within 30 days prior to entry

          5. The following laboratory values obtained within 30 prior to study entry:

             Absolute neutrophil count (ANC) ≥750/mm3 Hematocrit ≥30 Platelet count ≥40,000/mm3
             Calculated creatinine clearance (CrCl) ≥50 mL/min, as estimated by the Cockcroft-Gault
             equation* aspartate amino transferase (AST) serum glutamic oxalacetic transaminase
             (SGOT), amino alanine transferase (ALT) serum glutamic-pyruvic transaminase (SGPT),
             and alkaline phosphatase &lt;3 x upper limit of normal (ULN) total bilirubin ≤2.5 x ULN

             NOTE: If the potential subject is taking an atazanavir-containing regimen at the time
             of screening, total bilirubin ≤5 x ULN is acceptable

             * Calculation for the Cockcroft-Gault equation is available at
             https://www.fstrf.org/common/utilities/calculators/ccc.html

          6. Clinically significant fatigue (≥4.5 on the FSS)

          7. PHQ-9 Questionnaire score &lt;10

          8. ISI Questionnaire &lt;14

          9. On stable psychiatric medications for at least 8 weeks prior to enrollment.

         10. Ability and willingness of subject to provide a signed informed consent and comply
             with all study requirements

         11. Laboratory values and physical examination as judged by the principal investigator to
             be safe to participate

         12. Females of reproductive potential (women who have not been post-menopausal for at
             least 24 consecutive months, i.e., who have had menses within the preceding 24 months,
             or women who have not undergone surgical sterilization, specifically hysterectomy, or
             bilateral oophorectomy or tubal ligation) will need a negative serum or urine
             pregnancy test within 30 days prior to entry.

             NOTE: Acceptable documentation of hysterectomy and bilateral oophorectomy, tubal
             ligation, tubal micro-inserts, and menopause is self-reported history.

         13. All potential subjects must agree not to participate in the conception process (e.g.,
             active attempt to become pregnant or to impregnate, sperm donation, in vitro
             fertilization), and if participating in sexual activity that could lead to pregnancy,
             the subject/ partner must reliable methods of contraception (condoms, with or without
             a spermicidal agent; a diaphragm or cervical cap with spermicide; an intrauterine
             contraceptive device (IUD); or hormone-based contraceptive) while receiving study
             treatment. Subjects will be encourage to use a barrier method of contraception (e.g.
             condoms) along with hormonal contraceptives during administration of American ginseng.

        EXCLUSION CRITERIA

          1. Untreated hypothyroidism (TSH &gt;4.5 milli-international units per liter (mIU/L))

          2. Untreated or undertreated hypogonadism (calculated free testosterone below The lower
             limit of normal)

          3. Untreated or under-treated major depressive disorder

          4. No change in testosterone therapy within 6 weeks prior to screening

          5. As determined by the investigator, history of chronic or acute medical condition that
             in the opinion of the investigator would jeopardize safety of subjects participating
             in this study

          6. Hospitalization or therapy for serious illness within 30 days prior to study entry as
             judged by the investigator

          7. Known allergy/sensitivity or any hypersensitivity to components of American ginseng

          8. Active drug or alcohol use or dependence that, in the opinion of the site
             investigator, would interfere with adherence or subject compliance with study
             requirements (stable methadone treatment allowed)

          9. Current use or requirement for any medications prohibited with study treatment
             including warfarin. (Lists of prohibited medications are contained in the Prohibited
             Medications Section of the protocol)

         10. Pregnancy or breastfeeding

         11. Use of any immunomodulator (e.g., interferons, interleukins, systemic corticosteroids,
             cyclosporine), vaccine, or investigational therapy within 30 days prior to study entry

         12. Treatment with investigational study drugs/vaccines

         13. Co-enrolment in observational trials is allowed if the blood volume requirement does
             not exceed the Red Cross limits specified for this clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Andrade AS, Hendrix C, Parsons TL, Caballero B, Yuan CS, Flexner CW, Dobs AS, Brown TT. Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir. BMC Complement Altern Med. 2008 Aug 19;8:50. doi: 10.1186/1472-6882-8-50.</citation>
    <PMID>18713456</PMID>
  </reference>
  <reference>
    <citation>Barton DL, Soori GS, Bauer BA, Sloan JA, Johnson PA, Figueras C, Duane S, Mattar B, Liu H, Atherton PJ, Christensen B, Loprinzi CL. Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer. 2010 Feb;18(2):179-87. doi: 10.1007/s00520-009-0642-2. Epub 2009 May 6.</citation>
    <PMID>19415341</PMID>
  </reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>December 14, 2011</study_first_submitted>
  <study_first_submitted_qc>December 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2011</study_first_posted>
  <results_first_submitted>February 5, 2018</results_first_submitted>
  <results_first_submitted_qc>May 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 12, 2018</results_first_posted>
  <disposition_first_submitted>August 15, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>September 5, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 11, 2017</disposition_first_posted>
  <last_update_submitted>June 11, 2018</last_update_submitted>
  <last_update_submitted_qc>June 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fatigue</keyword>
  <keyword>HIV/AIDS</keyword>
  <keyword>American ginseng</keyword>
  <keyword>Panax quinquefolius</keyword>
  <keyword>Fatigue Severity Scale</keyword>
  <keyword>CD4 count</keyword>
  <keyword>plasma HIV RNA</keyword>
  <keyword>cytokines</keyword>
  <keyword>IL-6</keyword>
  <keyword>sTNFR1</keyword>
  <keyword>sTNFR2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were recruited from 2/13/13 through 10/19/15 from local HIV specialty clinics.</recruitment_details>
      <pre_assignment_details>Participants who met study criteria returned for an enrollment visit for randomization. Study drugs (placebo or ginseng) were dispensed by the Investigational Pharmacy. Participants were instructed to take study drugs daily for 28 days. They returned 2 wks after finishing taking study drugs for a final visit. No wash out or run-in periods.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>American Ginseng 1000 mg/Day</title>
          <description>4-week of American ginseng 1000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo for American Ginseng 1000 mg/Day</title>
          <description>4-week of placebo for American ginseng 1000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
        </group>
        <group group_id="P3">
          <title>American Ginseng 3000 mg/Day</title>
          <description>4-week of American ginseng 3000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
        </group>
        <group group_id="P4">
          <title>Placebo for American Ginseng 3000 mg/Day</title>
          <description>4-week of placebo for American ginseng 3000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants took the study product daily for 28 days. Participants returned 2 weeks after finishing taking the study product for a final evaluation. All participants completed questionnaires to quantify fatigue, were assessed for adverse events, and laboratory tests including inflammatory markers.</population>
      <group_list>
        <group group_id="B1">
          <title>American Ginseng 1000 mg/Day</title>
          <description>4-week of American ginseng 1000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo for American Ginseng 1000 mg/Day</title>
          <description>4-week of placebo for American ginseng 1000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
        </group>
        <group group_id="B3">
          <title>American Ginseng 3000 mg/Day</title>
          <description>4-week of American ginseng 3000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
        </group>
        <group group_id="B4">
          <title>Placebo for American Ginseng 3000 mg/Day</title>
          <description>4-week of placebo for American ginseng 3000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="16"/>
            <count group_id="B5" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.8" spread="7.5"/>
                    <measurement group_id="B2" value="52.1" spread="9.5"/>
                    <measurement group_id="B3" value="53.7" spread="6.8"/>
                    <measurement group_id="B4" value="50.2" spread="4.83"/>
                    <measurement group_id="B5" value="52.2" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Fatigue Severity Score (FSS)</title>
        <description>Change in FSS score from baseline to Week 4. The change in fatigue as measured by the FSS (Week 4 minus Baseline) using the Wilcoxon test. The FSS is a scale score ranging from 1 to 63 with higher scores indicative of more fatigue. A negative number indicates a decline in the FSS scale. Participants with FSS data at both times points were assessed.</description>
        <time_frame>From baseline to week 4 (28 days of study drugs)</time_frame>
        <population>There was one missing scale from the ginseng 3000 arm</population>
        <group_list>
          <group group_id="O1">
            <title>American Ginseng 1000 mg/Day</title>
            <description>4-week of American ginseng 1000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for American Ginseng 1000 mg/Day</title>
            <description>4-week of placebo for American ginseng 1000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
          </group>
          <group group_id="O3">
            <title>American Ginseng 3000 mg/Day</title>
            <description>4-week of American ginseng 3000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for American Ginseng 3000 mg/Day</title>
            <description>4-week of placebo for American ginseng 3000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fatigue Severity Score (FSS)</title>
          <description>Change in FSS score from baseline to Week 4. The change in fatigue as measured by the FSS (Week 4 minus Baseline) using the Wilcoxon test. The FSS is a scale score ranging from 1 to 63 with higher scores indicative of more fatigue. A negative number indicates a decline in the FSS scale. Participants with FSS data at both times points were assessed.</description>
          <population>There was one missing scale from the ginseng 3000 arm</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.7" spread="18.6"/>
                    <measurement group_id="O2" value="-16.3" spread="18.6"/>
                    <measurement group_id="O3" value="-16.9" spread="15"/>
                    <measurement group_id="O4" value="-21.6" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the changes from baseline to week 4 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the changes from baseline to week 4 are significantly different between arms</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Brief Fatigue Inventory</title>
        <description>Questionnaire: Change in the Brief Fatigue Inventory (BFI) from baseline to week 4. We compared BFI scores from baseline to week 4 in the ginseng 1000 and 3000 mg arms with the combined placebo arms. We used the BFI Question that assess &quot;Worst Fatigue&quot; score: 0 to 90 scale. Higher scores means more fatigue; negative values mean less fatigue.The BFI was used to supplement the data obtained from the FSS.</description>
        <time_frame>Change in BFI scores from baseline to week 4 (28 days of study drugs)</time_frame>
        <population>There was on missing questionnaire from the ginseng 3000 arm</population>
        <group_list>
          <group group_id="O1">
            <title>American Ginseng 1000 mg/Day</title>
            <description>4-week of American ginseng 1000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for American Ginseng 1000 mg/Day</title>
            <description>4-week of placebo for American ginseng 1000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
          </group>
          <group group_id="O3">
            <title>American Ginseng 3000 mg/Day</title>
            <description>4-week of American ginseng 3000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for American Ginseng 3000 mg/Day</title>
            <description>4-week of placebo for American ginseng 3000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Brief Fatigue Inventory</title>
          <description>Questionnaire: Change in the Brief Fatigue Inventory (BFI) from baseline to week 4. We compared BFI scores from baseline to week 4 in the ginseng 1000 and 3000 mg arms with the combined placebo arms. We used the BFI Question that assess &quot;Worst Fatigue&quot; score: 0 to 90 scale. Higher scores means more fatigue; negative values mean less fatigue.The BFI was used to supplement the data obtained from the FSS.</description>
          <population>There was on missing questionnaire from the ginseng 3000 arm</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.2" spread="34.3"/>
                    <measurement group_id="O2" value="-26.5" spread="28.5"/>
                    <measurement group_id="O3" value="-42.7" spread="32.4"/>
                    <measurement group_id="O4" value="-37.9" spread="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the changes from baseline to week 4 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1329</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the changes from baseline to week 4 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1191</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Epworth Sleepiness Scale</title>
        <description>Questionnaire: Change in Epworth Sleepiness Scale (ESS) score from baseline to week 4. The ESS is scale ranges from 0 to 24; higher scores mean worse sleep disorder while a negative score indicates less sleep disorder. The ESS was used to supplement the data obtained from the FSS.</description>
        <time_frame>From baseline to week 4 (28 days of study drugs)</time_frame>
        <population>There was one missing questionnaire from the ginseng 3000 arm</population>
        <group_list>
          <group group_id="O1">
            <title>American Ginseng 1000 mg/Day</title>
            <description>4-week of American ginseng 1000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for American Ginseng 1000 mg/Day</title>
            <description>4-week of placebo for American ginseng 1000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
          </group>
          <group group_id="O3">
            <title>American Ginseng 3000 mg/Day</title>
            <description>4-week of American ginseng 3000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for American Ginseng 3000 mg/Day</title>
            <description>4-week of placebo for American ginseng 3000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Epworth Sleepiness Scale</title>
          <description>Questionnaire: Change in Epworth Sleepiness Scale (ESS) score from baseline to week 4. The ESS is scale ranges from 0 to 24; higher scores mean worse sleep disorder while a negative score indicates less sleep disorder. The ESS was used to supplement the data obtained from the FSS.</description>
          <population>There was one missing questionnaire from the ginseng 3000 arm</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.74" spread="7.15"/>
                    <measurement group_id="O2" value="-6.35" spread="4.43"/>
                    <measurement group_id="O3" value="-6.97" spread="5.23"/>
                    <measurement group_id="O4" value="-5.93" spread="3.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the changes from baseline to week 4 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7454</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the changes from baseline to week 4 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7391</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Patient Health Questionnaire 9</title>
        <description>Questionnaire: Change in Patient Health Questionnaire 9 (PHQ9) score from baseline to week 4. The scale for the PHQ9 score ranges from 0 to 27; higher scores mean worse depression; negative scores indicate less depression. We compared PHQ 9 scores from baseline to week 4 in the ginseng 1000 and 3000 mg arms with the combined placebo arms. The PHQ9 was used to supplement the data obtained from the FSS.</description>
        <time_frame>From baseline to week 4 (28 days of study drugs)</time_frame>
        <population>There was one missed PHQ9 in the ginseng 3000 mg arm</population>
        <group_list>
          <group group_id="O1">
            <title>American Ginseng 1000 mg/Day</title>
            <description>4-week of American ginseng 1000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for American Ginseng 1000 mg/Day</title>
            <description>4-week of placebo for American ginseng 1000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
          </group>
          <group group_id="O3">
            <title>American Ginseng 3000 mg/Day</title>
            <description>4-week of American ginseng 3000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for American Ginseng 3000 mg/Day</title>
            <description>4-week of placebo for American ginseng 3000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Patient Health Questionnaire 9</title>
          <description>Questionnaire: Change in Patient Health Questionnaire 9 (PHQ9) score from baseline to week 4. The scale for the PHQ9 score ranges from 0 to 27; higher scores mean worse depression; negative scores indicate less depression. We compared PHQ 9 scores from baseline to week 4 in the ginseng 1000 and 3000 mg arms with the combined placebo arms. The PHQ9 was used to supplement the data obtained from the FSS.</description>
          <population>There was one missed PHQ9 in the ginseng 3000 mg arm</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.52" spread="4.76"/>
                    <measurement group_id="O2" value="-5.59" spread="4.84"/>
                    <measurement group_id="O3" value="-2.87" spread="4.20"/>
                    <measurement group_id="O4" value="-3.86" spread="3.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the changes from baseline to week 4 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6818</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the changes from baseline to week 4 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0579</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insomnia Severity Index</title>
        <description>Questionnaire: Change in Insomnia Severity Index (ISI) score from baseline to week 4. The ISI scale ranges from 0 to 28; higher scores mean worse insomnia while negative scores indicate less insomnia. The ISI was used to supplement the data obtained from the FSS.</description>
        <time_frame>From baseline to week 4 (28 days of study drugs)</time_frame>
        <population>There was one missing ISI in the ginseng 3000 mg arm</population>
        <group_list>
          <group group_id="O1">
            <title>American Ginseng 1000 mg/Day</title>
            <description>4-week of American ginseng 1000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for American Ginseng 1000 mg/Day</title>
            <description>4-week of placebo for American ginseng 1000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
          </group>
          <group group_id="O3">
            <title>American Ginseng 3000 mg/Day</title>
            <description>4-week of American ginseng 3000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for American Ginseng 3000 mg/Day</title>
            <description>4-week of placebo for American ginseng 3000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insomnia Severity Index</title>
          <description>Questionnaire: Change in Insomnia Severity Index (ISI) score from baseline to week 4. The ISI scale ranges from 0 to 28; higher scores mean worse insomnia while negative scores indicate less insomnia. The ISI was used to supplement the data obtained from the FSS.</description>
          <population>There was one missing ISI in the ginseng 3000 mg arm</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.9" spread="6.07"/>
                    <measurement group_id="O2" value="-5.47" spread="5.15"/>
                    <measurement group_id="O3" value="-3.43" spread="5.49"/>
                    <measurement group_id="O4" value="-3.57" spread="5.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the changes from baseline to week 4 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the changes from baseline to week 4 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.51</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Medical Outcomes Study HIV Health Survey</title>
        <description>Questionnaire: Change in Medical Outcomes Study (MOS) HIV Health Survey score from baseline to week 4. We evaluated the MOS Energy Fatigue scores; the MOS scale ranges from 0-100; higher scores mean more energy. The MOS was used to supplement the data obtained from the FSS.</description>
        <time_frame>From baseline to week 4 (28 days of study drugs)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>American Ginseng 1000 mg/Day</title>
            <description>4-week of American ginseng 1000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for American Ginseng 1000 mg/Day</title>
            <description>4-week of placebo for American ginseng 1000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
          </group>
          <group group_id="O3">
            <title>American Ginseng 3000 mg/Day</title>
            <description>4-week of American ginseng 3000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for American Ginseng 3000 mg/Day</title>
            <description>4-week of placebo for American ginseng 3000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Medical Outcomes Study HIV Health Survey</title>
          <description>Questionnaire: Change in Medical Outcomes Study (MOS) HIV Health Survey score from baseline to week 4. We evaluated the MOS Energy Fatigue scores; the MOS scale ranges from 0-100; higher scores mean more energy. The MOS was used to supplement the data obtained from the FSS.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" spread="20.9"/>
                    <measurement group_id="O2" value="17.6" spread="19.5"/>
                    <measurement group_id="O3" value="24.0" spread="22.0"/>
                    <measurement group_id="O4" value="23.1" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the changes from baseline to week 4 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7884</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the changes from baseline to week 4 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5532</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Clinical Global Impressions</title>
        <description>Questionnaire: Change in Clinical Global Impressions (CGI) scores from baseline to week 4. CGI is an instrument for making global assessments of worsening or improvement during interventional trials. The subject rates the change in the overall status since beginning the intervention (ranging from: very much improved, much improved, minimally improved, no change, and minimally worse). We assessed the number of participants who rated &quot;very much improved&quot;.</description>
        <time_frame>From baseline to week 4 (28 days of study drugs)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>American Ginseng 1000 mg/Day</title>
            <description>4-week of American ginseng 1000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for American Ginseng 1000 mg/Day</title>
            <description>4-week of placebo for American ginseng 1000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
          </group>
          <group group_id="O3">
            <title>American Ginseng 3000 mg/Day</title>
            <description>4-week of American ginseng 3000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for American Ginseng 3000 mg/Day</title>
            <description>4-week of placebo for American ginseng 3000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Clinical Global Impressions</title>
          <description>Questionnaire: Change in Clinical Global Impressions (CGI) scores from baseline to week 4. CGI is an instrument for making global assessments of worsening or improvement during interventional trials. The subject rates the change in the overall status since beginning the intervention (ranging from: very much improved, much improved, minimally improved, no change, and minimally worse). We assessed the number of participants who rated &quot;very much improved&quot;.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the changes from baseline to week 4 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9885</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the changes from baseline to week 4 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2898</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sides Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Markers</title>
        <description>Laboratory - Inflammatory Markers (IMs): Change in Interleukin (IL) -6 and soluble receptors of tumor necrosis factor (TNF) α 1 and 2 (sTNFR1 and sTNFR2) from baseline to week 4. Negative values indicate less change in inflammatory markers.</description>
        <time_frame>From baseline to week 4 (28 days of study drugs)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>American Ginseng 1000 mg/Day</title>
            <description>4-week of American ginseng 1000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for American Ginseng 1000 mg/Day</title>
            <description>4-week of placebo for American ginseng 1000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
          </group>
          <group group_id="O3">
            <title>American Ginseng 3000 mg/Day</title>
            <description>4-week of American ginseng 3000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for American Ginseng 3000 mg/Day</title>
            <description>4-week of placebo for American ginseng 3000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Markers</title>
          <description>Laboratory - Inflammatory Markers (IMs): Change in Interleukin (IL) -6 and soluble receptors of tumor necrosis factor (TNF) α 1 and 2 (sTNFR1 and sTNFR2) from baseline to week 4. Negative values indicate less change in inflammatory markers.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="1.18"/>
                    <measurement group_id="O2" value="0.53" spread="1.99"/>
                    <measurement group_id="O3" value="0.079" spread="1.63"/>
                    <measurement group_id="O4" value="0.33" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sTNFR1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" spread="135.5"/>
                    <measurement group_id="O2" value="-15.5" spread="154.5"/>
                    <measurement group_id="O3" value="15.2" spread="170.5"/>
                    <measurement group_id="O4" value="-6.24" spread="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sTNFR2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.5" spread="667.9"/>
                    <measurement group_id="O2" value="4.08" spread="580.5"/>
                    <measurement group_id="O3" value="-207.7" spread="1156.1"/>
                    <measurement group_id="O4" value="-201.7" spread="1156.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the IL-6 level changes from baseline to week 4 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.60</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the IL-6 level changes from baseline to week 4 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the sTNFR1 level changes from baseline to week 4 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.41</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the sTNFR1 level changes from baseline to week 4 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.72</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the sTNFR2 level changes from baseline to week 4 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the sTNFR2 level changes from baseline to week 4 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CD4 Cell Count</title>
        <description>Laboratory: Change in absolute cluster of differentiation 4 (CD4) cell count from baseline to week 5. Negative values mean decline in CD4 cell count.</description>
        <time_frame>From baseline to week 5 (28 days of study drugs)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>American Ginseng 1000 mg/Day</title>
            <description>4-week of American ginseng 1000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for American Ginseng 1000 mg/Day</title>
            <description>4-week of placebo for American ginseng 1000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
          </group>
          <group group_id="O3">
            <title>American Ginseng 3000 mg/Day</title>
            <description>4-week of American ginseng 3000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for American Ginseng 3000 mg/Day</title>
            <description>4-week of placebo for American ginseng 3000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CD4 Cell Count</title>
          <description>Laboratory: Change in absolute cluster of differentiation 4 (CD4) cell count from baseline to week 5. Negative values mean decline in CD4 cell count.</description>
          <units>cells per cubic millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45" spread="111.5"/>
                    <measurement group_id="O2" value="56.6" spread="147.5"/>
                    <measurement group_id="O3" value="-23.1" spread="148.4"/>
                    <measurement group_id="O4" value="34.4" spread="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the changes from baseline to week 5 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the changes from baseline to week 4 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.71</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma HIV RNA</title>
        <description>Laboratory: Change in plasma HIV RNA from baseline to week 4. A negative value means a drop in plasma HIV RNA.</description>
        <time_frame>From baseline to week 4 (28 days of study drugs)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>American Ginseng 1000 mg/Day</title>
            <description>4-week of American ginseng 1000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for American Ginseng 1000 mg/Day</title>
            <description>4-week of placebo for American ginseng 1000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
          </group>
          <group group_id="O3">
            <title>American Ginseng 3000 mg/Day</title>
            <description>4-week of American ginseng 3000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for American Ginseng 3000 mg/Day</title>
            <description>4-week of placebo for American ginseng 3000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma HIV RNA</title>
          <description>Laboratory: Change in plasma HIV RNA from baseline to week 4. A negative value means a drop in plasma HIV RNA.</description>
          <units>copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="6.19"/>
                    <measurement group_id="O2" value="-0.06" spread="4.78"/>
                    <measurement group_id="O3" value="1.32" spread="7.02"/>
                    <measurement group_id="O4" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the changes from baseline to week 4 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the changes from baseline to week 4 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in PROMIS Fatigue</title>
        <description>Questionnaire: Change in Patient-Reported Outcomes Measurement Information System (PROMIS) fatigue score from baseline to week 4. Change in PROMIS fatigue score from baseline to Week 4. The change in fatigue as measured by the PROMIS fatigue (Week 4 minus Baseline) using the Wilcoxon test. The PROMIS fatigue is a scale with normalized mean of 50 and standard deviation (SD) of 10. Higher mean values mean more fatigue and negative values indicate less fatigue.</description>
        <time_frame>From baseline to week 4 (28 days of study drugs).</time_frame>
        <population>There was one missed PROMIS fatigue questionnaire in the ginseng 3000 mg arm.</population>
        <group_list>
          <group group_id="O1">
            <title>American Ginseng 1000 mg/Day</title>
            <description>4-week of American ginseng 1000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for American Ginseng 1000 mg/Day</title>
            <description>4-week of placebo for American ginseng 1000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
          </group>
          <group group_id="O3">
            <title>American Ginseng 3000 mg/Day</title>
            <description>4-week of American ginseng 3000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for American Ginseng 3000 mg/Day</title>
            <description>4-week of placebo for American ginseng 3000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PROMIS Fatigue</title>
          <description>Questionnaire: Change in Patient-Reported Outcomes Measurement Information System (PROMIS) fatigue score from baseline to week 4. Change in PROMIS fatigue score from baseline to Week 4. The change in fatigue as measured by the PROMIS fatigue (Week 4 minus Baseline) using the Wilcoxon test. The PROMIS fatigue is a scale with normalized mean of 50 and standard deviation (SD) of 10. Higher mean values mean more fatigue and negative values indicate less fatigue.</description>
          <population>There was one missed PROMIS fatigue questionnaire in the ginseng 3000 mg arm.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5" spread="11.8"/>
                    <measurement group_id="O2" value="-11.1" spread="11.0"/>
                    <measurement group_id="O3" value="-11.4" spread="10.9"/>
                    <measurement group_id="O4" value="-9.49" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the changes from baseline to week 4 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.47</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Testing whether the changes from baseline to week 4 are significantly different between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.41</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2 sided Wilcoxon (Mann-Whitney)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events in the Ginseng and Placebo Arms</title>
        <description>Adverse events (AEs) were assessed from baseline to wk 4 using the NIH Division of AIDS (DAIDS) Grading Toxicity Table, a well known tool used by NIH networks for assessing the severity of AEs in participants enrolled in clinical trials. Reporting the number of participants in each arm who experienced adverse events.</description>
        <time_frame>From baseline to week 4 (28 days of study drugs)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>American Ginseng 1000 mg/Day</title>
            <description>4-week of American ginseng 1000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for American Ginseng 1000 mg/Day</title>
            <description>4-week of placebo for American ginseng 1000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
          </group>
          <group group_id="O3">
            <title>American Ginseng 3000 mg/Day</title>
            <description>4-week of American ginseng 3000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for American Ginseng 3000 mg/Day</title>
            <description>4-week of placebo for American ginseng 3000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events in the Ginseng and Placebo Arms</title>
          <description>Adverse events (AEs) were assessed from baseline to wk 4 using the NIH Division of AIDS (DAIDS) Grading Toxicity Table, a well known tool used by NIH networks for assessing the severity of AEs in participants enrolled in clinical trials. Reporting the number of participants in each arm who experienced adverse events.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <desc>The NIH Division of AIDS Toxicity table was used to grade averse event severity for this clinical trial. Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Potentially Life Threatening), Grade 5 (Death). Some data was lost and is no longer available for 1 participant in the Ginseng 1000 mg/day arm, and 2 participants in the Placebo for the Ginseng 3000 mg/Day arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>American Ginseng 1000 mg/Day</title>
          <description>4-week of American ginseng 1000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo for American Ginseng 1000 mg/Day</title>
          <description>4-week of placebo for American ginseng 1000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
        </group>
        <group group_id="E3">
          <title>American Ginseng 3000 mg/Day</title>
          <description>4-week of American ginseng 3000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.</description>
        </group>
        <group group_id="E4">
          <title>Placebo for American Ginseng 3000 mg/Day</title>
          <description>4-week of placebo for American ginseng 3000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>DAIDS Toxicity Table</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain Right Index Finger</sub_title>
                <description>Pain Right Index Finger</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <description>Abdominal Pain</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Right Flank Pain</sub_title>
                <description>Right Flank Pain</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased AST</sub_title>
                <description>Increased Aspartate aminotransferase (AST)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Low ANC</sub_title>
                <description>Low Absolute Neutrophil Count (ANC)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <description>Cellulitis Right Finger</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>Hyperglycemia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney Stone</sub_title>
                <description>Kidney Stone</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <description>Ureterolithiasis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <description>Bronchitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hip Replacement</sub_title>
                <description>Right Hip Replacement</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>DAIDS Toxicity Table</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased ANC</sub_title>
                <description>Decreased ANC</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Hypertension</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>Hyperglycemia</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Diarrhea</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E4" events="9" subjects_affected="5" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Fatigue</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT</sub_title>
                <description>Elevated Alanine Aminotransferase (ALT)</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Elevated AST</sub_title>
                <description>Elevated AST</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Elevated Alkaline Phosphatase</sub_title>
                <description>Elevated Alkaline Phosphatase</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Elevated Bilirubin</sub_title>
                <description>Elevated Bilirubin</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <description>Upper Respiratory Infection</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Potassium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Elevated Glucose</sub_title>
                <description>Elevated Glucose</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Diziness</sub_title>
                <description>Dizziness</description>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="32"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Headache</description>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="32"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E3" events="14" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Insomnia</description>
                <counts group_id="E1" events="17" subjects_affected="11" subjects_at_risk="32"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E3" events="18" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <description>Nervousness</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="32"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <description>Anxiety</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="32"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <description>Elevated Creatinine</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <description>Cough</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adriana Andrade</name_or_title>
      <organization>Johns Hokpins University</organization>
      <phone>410-955-7287</phone>
      <email>aandrade@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

